Plasma metabolomics disentangles T2DM- and CAD-specific dysmetabolism and identifies potential biomarkers for CAD risk escalation in diabetic patients.

ABSTRACT:

Background

Type 2 diabetes mellitus (T2DM) is a major driver of coronary artery disease (CAD). Prior studies often conflate T2DM- and CAD-specific metabolic alterations, limiting insights into CAD pathogenesis in T2DM. This study aimed to distinguish CAD-unique signatures from T2DM-specific dysmetabolism, and to identify potential metabolic biomarkers for CAD risk escalation in T2DM patients.

Methods

We performed an untargeted plasma metabolomic study with 123 healthy controls (HCs), 50 T2DM patients without CAD, and 155 T2DM patients with CAD. T2DM_CAD was defined as T2DM diagnosed at least 5 years prior to CAD, with coronary angiography-confirmed stenosis (> 30%) in major coronary arteries. Differential metabolites were identified via intergroup comparisons, with T2DM-spec

SUBMITTER: Hu T 

PROVIDER: S-EPMC12632129 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature